Streetbeat News

Stock Prices

GMDA

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2 as reported on November 14, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:34 pm

TMO

Thermo Fisher Scientific has authorized a new $4 billion share repurchase program, which has led to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:33 pm

GMDA

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:33 pm

ORCL

Over the past 10 years, Oracle (NYSE:ORCL) has delivered an average annual return of 12.72%, outperforming the market. A $1000 investment in ORCL a decade ago would be worth $3,294.02 today. Oracle's market cap stands at $318.45 billion.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 3:30 pm

GPN

Global Payments (NYSE:GPN) has delivered an average annual return of 13.63% over the past 10 years, outperforming the market by 3.97% annually. A $100 investment in GPN stock a decade ago would be worth $357.37 today. The company's current market capitalization stands at $29.29 billion.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 3:30 pm

TMO

Thermo Fisher Scientific's stock is trading higher following the announcement of a $4 billion share repurchase authorization. This buyback program reflects the company's confidence in its financial strength and commitment to delivering shareholder value.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:30 pm

ALNY

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $395.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:28 pm

TGT

Target Corp (NYSE:TGT) reported Q3 FY23 sales of $25.398 billion, surpassing estimates, with a 4.22% Y/Y decline. Comparable sales fell 4.9%, but gross margin expanded to 27.4% due to lower costs and favorable category mix. Operating income rose 28.8% to $1.3 billion. Adjusted EPS of $2.10 beat estimates of $1.48. Inventory was down 14% Y/Y, and dividends paid increased to $507 million. The company forecasts Q4 adjusted EPS of $1.90 - $2.60, with expected mid-single-digit sales decline. TGT shares surged 18.3% to $131.11.

Portfolio Pulse from Shivani Kumaresan

November 15, 2023 | 3:21 pm

CBSTF

MSOS

MSOX

The article discusses the current state and potential growth of the U.S. cannabis industry, highlighting the challenges such as taxation and stock custody issues. It mentions the sequential growth of TerrAscend and the resolution of a lawsuit in New York that could expedite the opening of new dispensaries. The New Jersey cannabis market is approaching $1 billion in sales, and Ohio is discussing marijuana legalization law amendments. A survey suggests cannabis is preferred over other sleep aids. The U.S. hemp industry's future hinges on the Farm Bill extension. Cannabis stocks showed volatility, with MSOS experiencing a significant rally. The article also touches on international developments in cannabis legalization and the need for policy change at the federal level.

Portfolio Pulse from Todd Harrison

November 15, 2023 | 3:16 pm

CRLBF

Cresco Labs Inc. reported a 9.4% year-over-year revenue decline in Q3 2023 to $190.5 million, despite strong margins and cash flow. The company's adjusted gross margin and EBITDA margin increased significantly, and it generated $62 million in operating cash flow in the first nine months. However, a net loss of $113.4 million was reported, mainly due to one-time impairment charges. Cresco's shares fell 3.125% to $1.55 post-market on Tuesday.

Portfolio Pulse from Jelena Martinovic

November 15, 2023 | 3:16 pm